|
|
 |
|
Viewing report
|
|
|
|
Cancer Diagnostic Testing World Markets
TriMark Publications, April 2008, Pages: 274
Cancer testing is one of the most important growth opportunities for the next three to five years in the diagnostics segment. The National Cancer Institute estimates that about ten million Americans have or have had some form of cancer. Overall costs of the disease are $126 billion annually. Pharmaceutical companies are developing more than 300 new medicines for cancer, some of which are in development for more than one type of the disease, for a total of more than 500 ongoing R&D projects.
The goal of this report is to review the market for tumor marker testing equipment and supplies using screening reagents and instruments for analysis of individual components in blood, serum or plasma. It defines the dollar volume of sales, both worldwide and in the U.S., and analyzes the factors that influence the size and the growth of the market segments. Also examined are the subsections of each market segment, including: the physician office labs, hospital labs and commercial laboratories. Additionally, the numbers of institutions using this type of testing and the factors that influence purchases are discussed. The report surveys almost all of the companies known to be marketing, manufacturing or developing instruments and reagents for the clinical point-of-care market in the U.S. Each company is discussed in depth with a section on its history, product line, business and marketing analysis, and a subjective commentary of the company’s market position.
By Purchasing This Report You Will Have:
- An improved understanding of the current state and future of the cancer diagnostic testing market.
- The latest information on the leading companies engaged in research and development and products in the pipeline.
- The leading perspective of recent cancer diagnostic developments and revelations.
- Knowledge of the cancer diagnostics market as an area of growth, research and investment.
Analysis includes the use of charts and graphs measuring product growth and trends within the marketplace. In addition, a discussion of research into the cancer diagnostics arena provides the reader with a deeper understanding of the possibilities for future treatment and avenues for possible research and development budgets. Company-specific information, including sales figures, product pipeline status and research and development trends is provided throughout the report. The report will:
- Identify viable technology drivers through a comprehensive look at platform technologies for cancer diagnostics, including, probe-based nucleic acid assays, microarrays and sequencing.
- Obtain a complete understanding of the chief cancer diagnostics tests-i.e., predictive, screening, prognostic, monitoring, pharmacogenomic and theranostic-from their basic principles to their applications.
- Discover feasible market opportunities by identifying high-growth applications in different clinical diagnostic areas, focusing on the biggest and expanding markets in oncology.
- Focus on global industry development through an in-depth analysis of the major world markets for cancer diagnostics, including growth forecasts.
This report answers the following questions in this report:
- What are the near-term business opportunities in the cancer diagnostics market?
- What are the current and forecasted sizes of the cancer diagnostics market?
- What are the business models currently used by companies in cancer diagnostics?
- How will manufacturers, researchers, physicians, patients and payers influence the cancer diagnostics market?
- What are the drivers and bottlenecks influencing the cancer diagnostics market?
- What are the technologies used in the cancer diagnostics sector?
- Who holds the proprietary rights to cancer diagnostics market technology?
- What are current applications of this technology?
- What regulatory processes must cancer diagnostics undergo in the United States, Japan and Europe?
- How will new cancer diagnostics change treatment and payment paradigms?
- How will cancer diagnostic testing reduce healthcare expenditures?
Product samples
A sample for this product is available. Please Login/Register to download this sample.
Also available
Point of Care Diagnostic Testing World Markets
Key Diagnostic Testing Markets
Women’s Health Diagnostic Testing
Molecular Diagnostics Markets
Cardiac Marker Diagnostic Testing Markets
High-Growth Diagnostic Testing Markets
Point of Care Diagnostic Testing Sector Trends
Biomarker Technology Platforms for Cancer Diagnoses and Therapies
Cancer Cell Therapy Markets
Companion Diagnostics in Personalized Medicine and Cancer Therapy
Companion Diagnostics in Personalized Medicine and Cancer Therapy
Cancer Therapeutics Markets
Cytology and HPV Testing World Markets
Cancer Bundle
Diagnostics Bundle
Customers who bought this item also bought
The US Cancer Diagnostics Market
The Spanish Cancer Diagnostics Market
The German Cancer Diagnostics Market
The Japanese Cancer Diagnostics Market
The UK Cancer Diagnostics Market
The French Cancer Diagnostics Market
The Italian Cancer Diagnostics Market
Biomarker Technology Platforms for Cancer Diagnoses and Therapies
The Cancer Diagnostics Market: Emerging Opportunities And Business Expansion Strategies
Companion Diagnostics in Personalized Medicine and Cancer Therapy
Innovations in Cancer: Novel Therapeutics, New Diagnostics and Future R&D Strategies
Cancer Therapeutics Markets
|
|
|
|
